From FDA labels and ClinicalTrials.gov

Do GLP-1s help after bariatric surgery?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists weight regain after bariatric surgery as an approved use, so prescribing one for it would be off-label. BARI-STEP (Semaglutide): At least a year after surgery, in people who had lost less than hoped, weight changed -18.0% on semaglutide 2.4 mg against +0.4% on placebo over 68 weeks. BARI-STEP on PubMed (pubmed.ncbi.nlm.nih.gov/42174253). ClinicalTrials.gov lists 50 trials of these medicines on it: 4 with posted results and 11 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

Published results

What the largest trials on weight regain after bariatric surgery found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

BARI-STEP

Semaglutide · 70 people · Better than the comparison · Placebo-controlled randomized trial

At least a year after surgery, in people who had lost less than hoped, weight changed -18.0% on semaglutide 2.4 mg against +0.4% on placebo over 68 weeks.

BARI-STEP on PubMed (pubmed.ncbi.nlm.nih.gov/42174253)

BARI-OPTIMISE

Liraglutide · 70 people · Better than the comparison · Placebo-controlled randomized trial

In people with poor weight loss after metabolic surgery and a suboptimal GLP-1 response, weight changed -8.82% on liraglutide 3 mg against -0.54% on placebo over 24 weeks.

BARI-OPTIMISE on PubMed (pubmed.ncbi.nlm.nih.gov/37494014)

The registry

Trials on weight regain after bariatric surgery, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide2419
Liraglutide1631
Tirzepatide601
Exenatide300
Mazdutide100
Posted results

What trials on weight regain after bariatric surgery reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT03115424Effect of GLP-1 Receptor Agonism After Sleeve GastrectomyLiraglutidePhase 346Weight (kilograms), baseline and 36 months, baseline. Sleeve Gastrectomy Saxenda: 127; Sleeve Gastrectomy Placebo: 130; Roux-en-Y Gastric (RYGB): 126.
NCT03048578Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass SurgeryLiraglutidePhase 4132Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test (percentage of participants), 12 Months. Saxenda: 76; Placebo: 17.
NOVO-GLP1Treatment of GLP-1 for Diabetic Bariatric PatientsSemaglutidePhase 43On ClinicalTrials.gov (clinicaltrials.gov)
NCT04883346Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve GastrectomyLiraglutidePhase 234On ClinicalTrials.gov (clinicaltrials.gov)
Recruiting now

Trials on weight regain after bariatric surgery taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth (clinicaltrials.gov/study/NCT06934655)SemaglutidePhase 3Nov 1, 2033
Impact GLP-1 Agonists Following Bariatric (clinicaltrials.gov/study/NCT06132477)SemaglutidePhase 4Jul 2030
Fibrosis Lessens After Metabolic Surgery (clinicaltrials.gov/study/NCT06374875)SemaglutidePhase 4Dec 31, 2029
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (clinicaltrials.gov/study/NCT07058155)SemaglutidePhase 4Feb 1, 2034
2024 Tirzepatide-Bariatric Surgery (clinicaltrials.gov/study/NCT06721507)TirzepatidePhase 4Dec 31, 2026
Bariatric Surgery Combined With GLP-1 Receptor Agonists Study (clinicaltrials.gov/study/NCT07336862)SemaglutidePhase 1/2Dec 2027
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study. (clinicaltrials.gov/study/NCT07732738)SemaglutideNot phasedDec 30, 2027
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity (clinicaltrials.gov/study/NCT07633639)SemaglutideNot phasedMay 1, 2028
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity (clinicaltrials.gov/study/NCT07901777)SemaglutideNot phasedNov 15, 2028
Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity (clinicaltrials.gov/study/NCT06720246)LiraglutideNot phasedMay 1, 2027
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents (clinicaltrials.gov/study/NCT06575738)SemaglutidePhase 1Oct 1, 2027
From PubMed

Newest papers on GLP-1s and weight regain after bariatric surgery

  • Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/43024141)

    Meta-analysis · Obes Surg · Nov 13, 2026 · Urbina J et al.

  • Acute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP-1 and Glycaemic Responses in Post-Bariatric Hypoglycaemia: A Randomised Crossover Study (pubmed.ncbi.nlm.nih.gov/42864266)

    Randomized trial · Diabetes Obes Metab · Oct 12, 2026 · Yang W et al.

  • [Efficacy and safety of GLP-1 receptor agonists combined with bariatric surgery for obesity: a timing-stratified systematic review] (pubmed.ncbi.nlm.nih.gov/42927970)

    Meta-analysis · Zhonghua Wei Chang Wai Ke Za Zhi · Oct 1, 2026 · He MC et al.

  • Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42700367)

    Meta-analysis · Endocrinol Diabetes Metab · Sep 1, 2026 · Shirmohammadi E et al.

  • The comparative effectiveness of bariatric operations versus GLP-1 RAs: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42660781)

    Meta-analysis · Surg Obes Relat Dis · Jul 29, 2026 · Campbell C et al.

  • Comparative Outcomes of Metabolic and Bariatric Surgery Versus GLP-1 Receptor Agonists: An Updated Systematic Review and Meta-Analysis of 14,548 Patients (pubmed.ncbi.nlm.nih.gov/42452903)

    Meta-analysis · J Laparoendosc Adv Surg Tech A · Jul 14, 2026 · Rivero-Moreno Y et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on weight regain after bariatric surgery

  • TrialNew Semaglutide study registered: Changes in Body Composition Following Pharmacological Treatment for Obesity. (clinicaltrials.gov/study/NCT07908940)
  • TrialNew Semaglutide study registered: Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity (clinicaltrials.gov/study/NCT07901777)
  • TrialNew Semaglutide study registered: Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia (clinicaltrials.gov/study/NCT07878494)
  • TrialNew Semaglutide study registered: Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) (clinicaltrials.gov/study/NCT07859150)
  • TrialNew Semaglutide study registered: Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain (clinicaltrials.gov/study/NCT07859163)
  • TrialNew Semaglutide study registered: Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery (clinicaltrials.gov/study/NCT07859176)
  • TrialNew Semaglutide study registered: Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher (clinicaltrials.gov/study/NCT07859137)
  • TrialNew Semaglutide study registered: Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery (clinicaltrials.gov/study/NCT07859189)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and weight regain after bariatric surgery: common questions

What did the largest trial on weight regain after bariatric surgery find?

BARI-STEP (Semaglutide, 70 people): At least a year after surgery, in people who had lost less than hoped, weight changed -18.0% on semaglutide 2.4 mg against +0.4% on placebo over 68 weeks.

Is any GLP-1 FDA approved for weight regain after bariatric surgery?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for weight regain after bariatric surgery?

Semaglutide, with 24 registered trials on it, then Liraglutide with 16. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for weight regain after bariatric surgery?

11 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.